Serum interleukin-17 levels are associated with nephritis in childhood-onset systemic lupus erythematosus

Abstract

OBJECTIVES:To determine the serum interleukin-17 (IL-17) levels in childhood-onset systemic lupus erythematosus patients and to evaluate the association between IL-17 and clinical manifestations, disease activity, laboratory findings and treatment.METHODS:We included 67 consecutive childhood-onset systemic lupus erythematosus patients [61 women; median age 18 years (range 11-31)], 55 first-degree relatives [50 women; median age 40 years (range 29-52)] and 47 age- and sex-matched healthy controls [42 women; median age 19 years (range 6-30)]. The childhood-onset systemic lupus erythematosus patients were assessed for clinical and laboratory systemic lupus erythematosus manifestations, disease activity [Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)], cumulative damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) Damage Index] and current drug use. Serum IL-17 levels were measured by an enzyme-linked immunosorbent assay using commercial kits.RESULTS:The median serum IL-17 level was 36.3 (range 17.36-105.92) pg/mL in childhood-onset systemic lupus erythematosus patients and 29.47 (15.16-62.17) pg/mL in healthy controls (p=0.009). We observed an association between serum IL-17 levels and active nephritis (p=0.01) and migraines (p=0.03). Serum IL-17 levels were not associated with disease activity (p=0.32), cumulative damage (p=0.34), or medication use (p=0.63).CONCLUSION:IL-17 is increased in childhood-onset systemic lupus erythematosus and may play a role in the pathogenesis of neuropsychiatric and renal manifestations. Longitudinal studies are necessary to determine the role of IL-17 in childhood-onset systemic lupus erythematosus.

IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis

“…Accordingly, patients with ANCA-associated vasculitis presented elevated serum levels of IL-17A and other Th17-related cytokines, such as IL-23 [ 89 ], whereas in ANCA-associated crescentic glomerulonephritis patients, only serum IL-17C but not IL-17A, F, or E levels were increased [ 90 ]. In addition, high serum and urine IL-17A levels were found in patients with systemic lupus erythematosus [ 91 , 92 ] and in other immune glomerulonephritis [ 93 , 94 ]. More recently, preclinical and clinical studies have shown the involvement of IL-17A in nonimmune nephropathies, including hypertensive [ 61 , 95 ] and diabetic nephropathy [ 96 , 97 ].…”

Relationship between Neutrophil-to-Lymphocyte Ratio and Systemic Lupus Erythematosus: A Meta-analysis

“…Systemic lupus erythematosus (SLE) is a chronic systematic autoimmune disease with high heterogeneity (1,2). SLE is more prevalent in women of reproductive age than in men (3)(4)(5). Although the etiology and pathogenesis of SLE have not been fully elucidated, the breakdown of immune tolerance induced by environmental stimulation and genetic factors is widely reported to play a core role in SLE (1,2,6,7).…”

Potential biomarkers for nivolumab therapy of metastatic renal cell carcinoma

“…Возможно, изучение растворимых форм sPD-L1 / PD-1 позволит преодолеть опухолевую гетерогенность и идентифицировать наиболее значимые предикторные и прогностические биомаркеры. Интерес представляет изучение концентрации интерлейкина-17А (interleukin-17А, IL-17А) в сыворотке крови, повышение которой отмечено у больных с аутоиммунными заболеваниями, в том числе и нефритами [13,14], а также трансформирующего фактора роста бета 1 (transforming growth factor beta 1, TGF-β1), являющегося основным иммуносупрессором.…”